Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
660-03-001 ISMRM Abstract

CEST imaging of natural killer cell-based immunotherapy for brain tumor

Primary: Contrast Mechanisms - CEST / APT / NOE
Secondary: Neuro - Tumors
660-03-001 · Advances in Chemical Exchange MRI: CEST, APT, and NOE I · Thursday, 14 May, 1:40 PM–2:35 PM · Digital Posters Row A
Keywords: Immunotherapy 3.0T magnetic resonance imaging Nanomaterial CEST MRI in vivo Glioblastoma Multiforme
Accepted
Tian ZHANG 1, Hang K DENG2, Hao ZHANG1, Yuan ZONG2, Ai P LYU2, Wai Po CHONG2, Kannie W. Y. Chan1,3,4,5,6,7
1Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China
2School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
3Hong Kong Centre for Cerebro-Cardiovascular Health Engineering (COCHE), Hong Kong, China
4Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, United States of America
5State Key Laboratory of Terehertz and Millimeter Waves, City University of Hong Kong, Hong Kong, China
6Tung Biomedical Sciences Centre (TBSC), City University of Hong Kong, Hong Kong, China
7Institute of Digital Medicine, City University of Hong Kong, Hong Kong, China
Presenting Author: Tian ZHANG

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. [1] A. Bikfalvi et al., "Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023)," Trends Cancer, vol. 9, no. 8, p. 692, Aug 2023, doi: 10.1016/j.trecan.2023.02.006. [doi]
2. [2] A. Gras Navarro, A. T. Bjorklund, and M. Chekenya, "Therapeutic potential and challenges of natural killer cells in treatment of solid tumors," Front Immunol, vol. 6, p. 202, 2015, doi: 10.3389/fimmu.2015.00202. [doi]
3. [3] H. Shaim et al., "Targeting the alphav integrin/TGF-beta axis improves natural killer cell function against glioblastoma stem cells," J Clin Invest, vol. 131, no. 14, Jul 15 2021, doi: 10.1172/JCI142116. [doi]
4. [4] T. Zhang et al., "Regulatory T cell intravitreal delivery using hyaluronan methylcellulose hydrogel improves therapeutic efficacy in experimental autoimmune uveitis," Biomater Adv, vol. 151, p. 213496, Aug 2023, doi: 10.1016/j.bioadv.2023.213496. [doi]
5. [5] J. Huang, Z. Chen, S. W. Park, J. H. C. Lai, and K. W. Y. Chan, "Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges," Pharmaceutics, vol. 14, no. 2, Feb 20 2022, doi: 10.3390/pharmaceutics14020451. [doi]
6. [6] J. Zhou, B. Lal, D. A. Wilson, J. Laterra, and P. C. van Zijl, "Amide proton transfer (APT) contrast for imaging of brain tumors," Magn Reson Med, vol. 50, no. 6, pp. 1120-6, Dec 2003, doi: 10.1002/mrm.10651. [doi]
7. [7] S. W. Park et al., "Preclinical Application of CEST MRI to Detect Early and Regional Tumor Response to Local Brain Tumor Treatment," Pharmaceutics, vol. 16, no. 1, Jan 12 2024, doi: 10.3390/pharmaceutics16010101. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/660-03-001